ADORA3 and cancer: When breast cancer A3 adenosine receptor was blocked with antagonist PSB-10 within the microfluidic device, significantly increased cancer cell extravasation (32.4 ± 7.7% vs. 8.2 ± 2.3%) was observed compared to non-treated controls.